WuXi Biologics (2269.HK), a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, has received EMA GMP certificates for the production of Trogarzo at its cGMP Drug Substance and Drug Product manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai, it was reported yesterday.
The product is developed by TaiMed Biologics and marketed in the United States and EU by Theratechnologies.
WuXi Biologics said that the certification further endorses its systems and solid reputation as a leading global bio-manufacturing player.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval